secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-10-31T23:59:59+00:00
Accession:  0001437749-25-032512
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Robert Ferrara resigns; David Deming appointed Lead Independent Director
--------------------------------------------------------------------------------

- Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.
- Board reduced from 6 to 5 members; no vacancies remain.
- David Deming appointed Lead Independent Director; brings 30+ yrs investment banking (JP Morgan).
- Deming joined Phio Board in Feb 2025; serves on Nominating Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925032512/0001437749-25-032512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925032512/phio20251030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer